2 ms·
> I’m not sure this is by itself all that exciting This actually seems pretty significant. 1) It gets us closer to understanding the pathology: >> It also su
by echelon 4y ago
> I’m not sure this is by itself all that exciting
This actually seems pretty significant.
1) It gets us closer to understanding the pathology:
>> It also suggests that alpha-synuclein aggregation in spinal fluid is not a life-long trait but rather acquired as part of a disease biology process that ultimately gives rise to symptoms.
2) It gives us a higher resolution of detection.
>> αSyn-SAA can distinguish Parkinson’s from control volunteers with a stunningly robust sensitivity of 88 percent and specificity of 96 percent.
3) It shows different disease subtypes or mechanisms:
>> These results suggest that not all cases of clinical Parkinson’s symptoms are associated with the accumulation of alpha-synuclein aggregates as detected by this assay, and that LRRK2 variant carriers, in particular, may not show this pathology.
4) It gets us earlier signal:
>> This finding suggests that synuclein pathology could be detectable by this assay earlier than dopamine dysfunction is seen with DAT imaging, extending the window in which it may be possible to intervene with preventive therapies.
This is a valuable tool that will shed light on the entire disease pathology and guide further research and investigation into treatments.